Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000319673
Ethics application status
Approved
Date submitted
17/03/2023
Date registered
24/03/2023
Date last updated
3/04/2024
Date data sharing statement initially provided
24/03/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
A trial to assess the short-term efficacy of spectacle films and contact lenses in myopic children
Query!
Scientific title
Prospective, cross-over pilot trial to assess the short-term efficacy of novel myopia management spectacle films and contact lenses when worn by children.
Query!
Secondary ID [1]
309217
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myopia
329360
0
Query!
Condition category
Condition code
Eye
326304
326304
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This will be a prospective, randomised cross-over clinical trial. Participants will choose to either wear either study products (contact lenses or spectacles: i.e., a participant will wear one or the other, not both) for 14 months.
Contact lenses are made from ocufilcon D material and are replaced daily. A single vision contact lens will serve as the control, and a single vision contact lens with a tinted edge pattern will serve as the test. Contact lens wear will be contralateral, and the eye first wearing the control or test will be randomly determined. Contact lenses will be worn for 6 months. A cross-over will occur at 6 months so that the eye wearing the control will wear the test, and the eye wearing the test will wear the control. Participants will wear contact lenses for a further 6 months. The minimum wear time for contact lenses will be 5 days per week and 6 hours per day to a maximum of 16 hours per day. The distance power of the contact lenses will be power matched to the participant’s myopic refractive error. At the conclusion of 12 months of wear, participants will wear bilateral control contact lenses for a further 2 months.
Standard spectacles made with single vision lenses will be worn. A single vision spectacle lens will serve as the control, and a single vision spectacle lens with a spectacle film adhered on top of the spectacle lens containing an edge pattern will serve as the test. The spectacle film is made from polycarbonate material. Participants will control spectacle lenses bilaterally for 6 months. A cross-over will occur at 6 months and participants will wear spectacle test bilaterally for a further 6 months. . The minimum wear time for spectacles will be 5 days per week and 6 hours per day, with no daily maximum. Participants will choose a frame design from a designated pool of standard frames. Fittings will be confirmed by an optometrist. The distance power of the spectacle lenses will be power matched to the participant's myopic refractive error. At the conclusion of 12 months of wear, participants will wear bilateral control spectacle lenses for a further 2 months.
Each participant will attend 9 visits comprising visit 1 (baseline), visit 2 (study product dispensed), visit 3, visit 4, visit 5 (cross-over occurs), visit 6, visit 7, visit 8 (cross-over occurs), and visit 9.
Visit 1 will be approximately 45 min duration and visits 2-9 will be approximately 30 min duration. The timing between visits 1 and 2 will be approximately 2 weeks. The timing between visits 2-9 will be approximately 2 months.
Visit 1 will comprise standard subjective refraction, measurement of visual acuity obtained with refraction, and measurement of axial length. A standard Snellen visual acuity chart will be used to measure visual acuity and a standard optical biometer will be used to measure axial length. Visual acuity with study product and axial length will be measured at visits 2-9.
All assessments will be carried out by an optometrist. Participants will be instructed to wear study product as per the schedule and to return all study product. There is no 'wash-out' period at the cross-over (visit 5). Compliance will be assessed by verbal questioning of participants.
Query!
Intervention code [1]
325662
0
Treatment: Devices
Query!
Comparator / control treatment
For those wearing contact lenses, this is a contralateral study for the first 12 months and a bilateral study for the last 2 months. for those wearing contact lenses. Participants will wear a control lens in one eye and a test lens in the other eye. The allocation of test/control is randomised. For contact lenses, a single vision contact lens with no tinted edge pattern will serve as the control, and a single vision contact lens with a tinted edge pattern will serve as the test. At the 6-month visit, the test/control lens will be swapped between eyes. At the 12-month visit, participants will wear bilateral control for a further 2 months.
This is a bilateral study for those wearing spectacles. Participants will initially wear bilateral control followed by bilateral test. For spectacles, a single vision contact lens will serve as the control and a single vision spectacle lens with a spectacle film adhered to the top of the spectacle lens containing an edge pattern will serve as the test. Participants will wear bilateral control for the first 6 months, bilateral test for the next 6 months, and bilateral control for a further 2 months.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
334170
0
Difference in axial length between eyes when wearing the control and eyes when wearing the test. Axial length will be measured using a standard optical biometer.
Query!
Assessment method [1]
334170
0
Query!
Timepoint [1]
334170
0
At visit 2 (approximately 2 weeks post-enrolment)
At visit 3 (approximately 2.5 months post-enrolment)
At visit 4 (approximately 4.5 months post-enrolment)
At visit 5 (approximately 6.5 months post-enrolment)
At visit 6 (approximately 8.5 months post-enrolment)
At visit 7 (approximately 10.5 months post-enrolment)
At visit 8 (approximately 12.5 months post-enrolment)
Query!
Secondary outcome [1]
419642
0
Difference in visual acuity between the eye wearing the control and the eye wearing the test. Visual acuity will be measured using a standard Snellen letter chart..
Query!
Assessment method [1]
419642
0
Query!
Timepoint [1]
419642
0
At visit 2 (approximately 2 weeks post-enrolment)
At visit 3 (approximately 2.5 months post-enrolment)
At visit 4 (approximately 4.5 months post-enrolment)
At visit 5 (approximately 6.5 months post-enrolment)
At visit 6 (approximately 8.5 months post-enrolment)
At visit 7 (approximately 10.5 months post-enrolment)
At visit 8 (approximately 12.5 months post-enrolment)
Query!
Secondary outcome [2]
419643
0
To assess for rebound effects in terms of rate of change of axial length when control compared to test. Axial length will be measured using a standard optical biometer.
Query!
Assessment method [2]
419643
0
Query!
Timepoint [2]
419643
0
At visit 9 (approximately 14.5 months post-enrolment)
Query!
Eligibility
Key inclusion criteria
Aged between 7-15 years inclusive
Have read, understood and signed informed assent
Parents have read, understood and signed informed consent
Adhere to study requirements, wear study products and maintain visit schedule
Have good general health and normal ocular health
Best-corrected high contrast visual acuity of 6/7.6 or better in each eye
If wearing spectacle study product: Spectacle refraction of:
-sphere component between -0.50DS and -4.00DS inclusive and spherical equivalent less than or equal to -0.75D
-Astigmatic correction between 0DC and -1.50DC inclusive
If wearing contact lens study product: Spectacle refraction of:
-sphere component less than or equal to -0.50D and spherical equivalent between -0.75D and -4.00D inclusive
-Astigmatic correction between 0DC and -1.00DC inclusive
Query!
Minimum age
7
Years
Query!
Query!
Maximum age
15
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Current or use within 12 months of myopia management options including but not limited to
-Bifocal/multifocal spectacles or contact lenses
-Orthokeratology
-Atropine/pirenzepine pharmacological agents
If contact lenses are the chosen study product: contraindications to contact lens wear, including any pre-existing ocular irritation, injury, or condition (including infection or disease) of the cornea, conjunctiva or eyelids
Any systemic disease that adversely affects ocular health e.g., diabetes, Graves’ disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus.
Use of or a need for concurrent category S3 and above ocular medication at enrolment.
Eye surgery within 12 weeks immediately prior to enrolment for this trial.
Keratoconus
Manifest strabismus
Known allergy or intolerance to ingredients in any of the clinical trial products.
Currently enrolled in another clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation not concealed
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Comparisons will be between eyes wearing control or test product. Assuming a 6-monthly progression in axial length of 0.16 mm with single vision (control) contact lenses and a standard deviation (SD) of 0.10 mm, 24 participants are required to detect a 40% reduction in axial length with the test contact lens compared to the contralateral control contact lens at the 5% level of significance and 80% power for a 2-tailed distribution. Assuming a 20% drop-out, a minimum of 30 participants are required to wear contact lenses.
The current clinical trial aims to enrol the same number of participants to wear spectacles (i.e., 30 participants). Assuming a 6-monthly progression of 0.20 mm with single vision (control) spectacles and a SD of 0.10 mm, a sample size of 24 will provide >90% power for a 2-tailed distribution to demonstrate a 40% reduction in axial length with the test spectacle lens compared to the contralateral control spectacle lens at the 5% level of significance.
Primary and secondary outcomes will be summarised as means ± standard deviation. For the primary outcome (axial length), data from multiple visits and both eyes within the same participant are available for the analysis. Therefore, to account for the correlation of data collected within the same participant, a random effects mixed model will be used to compare the treatment effect on the primary endpoint over the study period. Participant and eye (nested within participant) will be included as random effects in the model to account for the correlation between repeated measures and between eyes within the same participant. The treatment effect (difference in change from initial dispense in axial length between each test product and control product) and its two-sided 95% confidence intervals at each assessment visit will be estimated from the model.
The secondary endpoints comprise visual acuity and rebound effects (the rate of change of axial length measurements between control and test products when control is worn after test). A similar random effects mixed model to the primary endpoint will be used for the analysis.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
9/01/2024
Query!
Actual
29/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
2
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment postcode(s) [1]
39851
0
2019 - Botany
Query!
Recruitment postcode(s) [2]
41821
0
2300 - Newcastle
Query!
Recruitment postcode(s) [3]
41822
0
3175 - Dandenong
Query!
Recruitment postcode(s) [4]
41823
0
2046 - Five Dock
Query!
Recruitment postcode(s) [5]
41824
0
3630 - Shepparton
Query!
Recruitment postcode(s) [6]
41825
0
2095 - Manly
Query!
Recruitment postcode(s) [7]
41826
0
2200 - Bankstown
Query!
Recruitment postcode(s) [8]
41827
0
4350 - Toowoomba
Query!
Recruitment postcode(s) [9]
41828
0
2154 - Castle Hill
Query!
Recruitment postcode(s) [10]
42185
0
3053 - Carlton
Query!
Recruitment postcode(s) [11]
42325
0
3053 - Carlton South
Query!
Funding & Sponsors
Funding source category [1]
313406
0
Commercial sector/Industry
Query!
Name [1]
313406
0
nthalmic Pty Ltd
Query!
Address [1]
313406
0
Suite L2, Level 3, Lakes Business Park,
2A Lord St,
Botany NSW 2019
Query!
Country [1]
313406
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
nthalmic Pty Ltd
Query!
Address
Suite L2, Level 3, Lakes Business Park,
2A Lord St,
Botany NSW 2019
Query!
Country
Australia
Query!
Secondary sponsor category [1]
315172
0
None
Query!
Name [1]
315172
0
Query!
Address [1]
315172
0
Query!
Country [1]
315172
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
312623
0
Bellberry Human Research Ethics Committee
Query!
Ethics committee address [1]
312623
0
123 Glen Osmond Rd
Eastwood
South Australia 5063
Query!
Ethics committee country [1]
312623
0
Australia
Query!
Date submitted for ethics approval [1]
312623
0
30/03/2023
Query!
Approval date [1]
312623
0
12/07/2023
Query!
Ethics approval number [1]
312623
0
Query!
Summary
Brief summary
There are two purposes to this trial. First, to assess the rate of change in axial length when wearing single vision contact lenses with an edge pattern against single vision contact lenses with no edge pattern. Second, to assess the rate of change in axial length when wearing single vision spectacle lenses with a spectacle film containing an edge pattern and adhered on top of the spectacle lens and single vision spectacle lenses with no spectacle film (i.e., no edge pattern). Axial length will be measured with a standard optical biometer. Contact lenses are made from ocufilcon D and spectacle films are made from polycarbonate. It is hypothesised that study products containing edge patterns will have a lower rate of change in axial length.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
125322
0
Dr Daniel Tilia
Query!
Address
125322
0
nthalmic Pty Ltd
Suite L2, Level 3, Lakes Business Park,
2A Lord St.
Botany NSW 2019
Query!
Country
125322
0
Australia
Query!
Phone
125322
0
+61 290377700
Query!
Fax
125322
0
Query!
Email
125322
0
[email protected]
Query!
Contact person for public queries
Name
125323
0
Ms Kathleen Laarakkers
Query!
Address
125323
0
nthalmic Pty Ltd
Suite L2, Level 3, Lakes Business Park,
2A Lord St.
Botany NSW 2019
Query!
Country
125323
0
Australia
Query!
Phone
125323
0
+61 290377700
Query!
Fax
125323
0
Query!
Email
125323
0
[email protected]
Query!
Contact person for scientific queries
Name
125324
0
Dr Daniel Tilia
Query!
Address
125324
0
nthalmic Pty Ltd
Suite L2, Level 3, Lakes Business Park,
2A Lord St.
Botany NSW 2019
Query!
Country
125324
0
Australia
Query!
Phone
125324
0
+61 290377700
Query!
Fax
125324
0
Query!
Email
125324
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Individual participant data will not be published. However, trial results, recorded as group means plus/minus SD and their statistical analysis may be published in scientific journals
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF